Jane Street Group LLC Reduces Stake in Precigen, Inc. (NASDAQ:PGEN)

Jane Street Group LLC reduced its position in Precigen, Inc. (NASDAQ:PGEN) by 47.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 65,082 shares of the biotechnology company’s stock after selling 59,003 shares during the quarter. Jane Street Group LLC’s holdings in Precigen were worth $62,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. SG Americas Securities LLC increased its position in Precigen by 44.2% during the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 13,823 shares during the period. Exchange Traded Concepts LLC grew its stake in Precigen by 10.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 167,496 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 15,525 shares during the last quarter. Stifel Financial Corp boosted its position in Precigen by 94.9% in the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 15,680 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Precigen by 40.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock worth $90,000 after buying an additional 16,486 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in Precigen by 56.7% during the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 18,097 shares during the period. Institutional investors own 33.51% of the company’s stock.

Analyst Ratings Changes

PGEN has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Precigen in a research report on Friday, November 15th. JMP Securities reissued a “market outperform” rating and set a $5.00 price target on shares of Precigen in a research report on Tuesday. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $6.33.

Precigen Price Performance

NASDAQ PGEN opened at $1.13 on Thursday. The company has a market cap of $330.94 million, a P/E ratio of -2.05 and a beta of 1.65. Precigen, Inc. has a 1-year low of $0.65 and a 1-year high of $1.93. The stock has a 50-day moving average of $0.90 and a two-hundred day moving average of $1.07.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.